Document E5rqarp855ogVZ8Qy8vmMDNN

FILE NAME: CTFA (CTFA) DATE: 1976 Mar 31 DOC#: CTFA031 DOCUMENT DESCRIPTION: Meeting Minutes-CTFA Talc Subcommittee V. ; * ' > * + -, v?r*4-- tt &*`i :- ? V g f . % 1 5 -The Cosmetic, Toiletry and Fragrance Association, Inc. 1133 IS Ih STREET, N.W., WASHINGTON. D.C. 20005 - 202/331,1770 TELEX 00-2673 James H.fjMClfottfcrfitnf Norman F. Eslrln, Ph.D. V J f finthunt-- tit tt TALC SUBCOMMITTEE 'm i n u t e s iSV u'+'*>;i > r * ' av V.'-*.%i- ^3 &S ' **,` , y ^*{ i*'*iT:;J C 'T.,;,^1 .r,*>V;/ 3*1 * k -rv.1 3?s& > Ajr-T4>V.*:t*-**% Xr^*rv'i'.*V*CVV: ut<~ KW#fe~#k I y**:*u*' ** P ^ T r '5 te * *' " : A meeting of the Ta-lc Subcommittee was held on March 31,-.1276, " at Bristol-Myers, 225 Long. Avenue, Hillside, New Jersey. Those in attendance were: ` .. . *. George Sandland*, Bristol-Myers CHMWU) , < John Clements, Pfizer, Inc. # '`Christopher. Costello, Colgate-Palmolive . .. - * John- Facq/ Colgate-Palmolive ' . ` ' Allan Harvey,. R.T* Vanderbilt Co., Inc. . . ** VGeorge Lee, Johnson * Johnson - ... *. ,. * .*' - Say Mrammes,: Whittaker, Clark a Daniels , "-Roderick J-Jundy, Sterling Drug Inc. * , - ** * fcoJii* Murino;'-'Cyprus Industrial..,,itinerals . **W Fred Itoesch, Whittaker, Clark & Daniels w ' . ,Robert Rolle, Johnson & Johnson ` , " .Joseph SjLmko,. -Colgate-Palmolive.-? ' \. - , , ``,;;jiekry Smith, Fabergte . r, , ** . -, `'-Harold .tanlex, Charles Pfizer Co* ` . .* --*' 1 'Ian Stewart, .Walter C. McCrone Assoc., Inc',' 5 . , ** : * ,Robert Suffis, Hennen Co. 4 . ' ** < \ % r -John Travers, Avon Products, Inc, 4 -j-'j Ronald Yakupcin, Kolmar Labs. \ \ N o r m a n EstrinCTFA. -. V - Sndlan^fopeneditile meeting and proceeded with the agenda. . ' % * 4 * jy/zi 4.; * *A JL w ***** 1 * s . X* "Collaborative Study . * - .1 u ;* *Mr. Lee and Dr Rolle updated the Subcommittee on reports r> - - of'-recent gathering-of sampies-by the Mi, Sinai group, ft ; 1' suggestion; wa? made that individual companies write directly -to Mt. Sinai*;s.management oh. th.e lack of'creditability of `* .* Langer* results when applied to theft specific products. r's&i*** a ^.*`v,.v I }`-*- * \` P Tr 'D 4 Ex. No.: .^ 1 , * .4 ^ : 1 hiI ^ t Date: jMpb Shirley q ! Casilan, CSR No. 12361 EXHIBlft K S' WIT: CONFIDENTIAL PF1 MO .00001785 The advantages and disadvantages were discussed in detail of '*. engaging in a collaborative study. 'It'was generally felt the . ` study could not be successful if there ere restrictions on which * talcs can be gathered. Many members favored engaging a collabora *tive study*. Dr. Estrin suggested a proposal be put together to be presented to the CTFA Board of Directors (as was done in the case of the microbiological contents study several years ago). A subcommittee was organized to draw up this proposal consistingr of Mr. Sufis,*Mr. Lee and chaired, by Mr. Sandland. V t * * 2. Periodic Reporting The Subcommittee agreed on the success of the presentation of , _ summary reports given to.the PDA.. Dr. Estrin suggested the .! Subcommittee should not obligate -itself to give periodic reports to FDA but urged members to build tlieir data base so . that at some time in the future the Subcommittee can decide - whether the time is right to present FDA with an update * on industry analysis. . . 3. ' Revie"w1of"Talc < " * Th planned review of talc by the Miscellaneous <3TC Drug > tPanel'was noted1. It was suggested CTFA begin "at once to plan , for a presentation to be made by a panel of experts including independent experts, talc suppliers and manufacturers. The '.-* actual data for consideration by the Miseellkencus Panel of . ,,summary information on talc was not known. 5. Animal Studies * , . * '* * . . Dr, `-Esfcrih suggested consideration be given to planning animal -- studies.. ,talc which may not be covered adequately by previous studies. Dr. Travers, Mr.'Roesch and Mr/ Lee will coordinate activities involving Dr. Gressel and Dr. Finkalstein to investigate this possibility. 6. -Sampling **. The Subcommittee agreed CTFA should not address the issue . raised by Mr. Eiermann and Dr. Schaffaer further with the FDA. There being no further business, the meeting adjourned. Jorman F..Estrin, Fh.D . Vice President - Science NFEsmp-